YMRC
CYTK icon

Yorktown Management & Research Company’s Cytokinetics CYTK Stock Holding History

Yorktown Management & Research Company’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Buy
7,750
+3,000
+63% +$215K 0.4% 79
2026
Q1 		$313K Buy
+4,750
New +$302K 0.26% 146

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Yorktown Management & Research Company's CYTK Position: Q2 2026 in Review

Yorktown Management & Research Company increased its Cytokinetics (CYTK) stake by 63% in Q2 2026, buying an estimated $215K and bringing the position to 7,750 shares worth $660K. The position accounts for 0.4% of the portfolio, ranked #79.

Yorktown Management & Research Company first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Yorktown Management & Research Company held 7,750 shares of Cytokinetics worth $660K as of Q2 2026.
  • Yorktown Management & Research Company bought 3,000 Cytokinetics shares in Q2 2026, an estimated $215K.
  • Cytokinetics made up 0.4% of Yorktown Management & Research Company's portfolio in Q2 2026, its #79 holding.
  • Yorktown Management & Research Company first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 200 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.